Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of 145.21 million. The enterprise value is 96.39 million.
| Market Cap | 145.21M |
| Enterprise Value | 96.39M |
Important Dates
The last earnings date was Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 241.97 million shares outstanding. The number of shares has increased by 7.84% in one year.
| Current Share Class | 241.97M |
| Shares Outstanding | 241.97M |
| Shares Change (YoY) | +7.84% |
| Shares Change (QoQ) | +2.55% |
| Owned by Insiders (%) | 1.49% |
| Owned by Institutions (%) | 0.17% |
| Float | 238.37M |
Valuation Ratios
The trailing PE ratio is 3.80 and the forward PE ratio is 53.11.
| PE Ratio | 3.80 |
| Forward PE | 53.11 |
| PS Ratio | 0.57 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | 9.81 |
| P/OCF Ratio | 9.52 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.84, with an EV/FCF ratio of 6.51.
| EV / Earnings | 2.60 |
| EV / Sales | 0.38 |
| EV / EBITDA | 1.84 |
| EV / EBIT | 2.52 |
| EV / FCF | 6.51 |
Financial Position
The company has a current ratio of 1.71, with a Debt / Equity ratio of 0.13.
| Current Ratio | 1.71 |
| Quick Ratio | 1.54 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | 0.82 |
| Interest Coverage | 16.38 |
Financial Efficiency
Return on equity (ROE) is 53.10% and return on invested capital (ROIC) is 91.74%.
| Return on Equity (ROE) | 53.10% |
| Return on Assets (ROA) | 14.09% |
| Return on Invested Capital (ROIC) | 91.74% |
| Return on Capital Employed (ROCE) | 36.99% |
| Weighted Average Cost of Capital (WACC) | 11.39% |
| Revenue Per Employee | 3.93M |
| Profits Per Employee | 570,723 |
| Employee Count | 65 |
| Asset Turnover | 1.51 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid 410,000 in taxes.
| Income Tax | 410,000 |
| Effective Tax Rate | 1.09% |
Stock Price Statistics
The stock price has increased by +33.36% in the last 52 weeks. The beta is 1.18, so Vaxart's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | +33.36% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.52 |
| Relative Strength Index (RSI) | 38.69 |
| Average Volume (20 Days) | 468,573 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.77 |
Income Statement
In the last 12 months, Vaxart had revenue of 255.61 million and earned 37.10 million in profits. Earnings per share was 0.16.
| Revenue | 255.61M |
| Gross Profit | 55.36M |
| Operating Income | 38.18M |
| Pretax Income | 37.51M |
| Net Income | 37.10M |
| EBITDA | 45.64M |
| EBIT | 38.18M |
| Earnings Per Share (EPS) | 0.16 |
Balance Sheet
The company has 61.02 million in cash and 12.20 million in debt, with a net cash position of 48.82 million or 0.20 per share.
| Cash & Cash Equivalents | 61.02M |
| Total Debt | 12.20M |
| Net Cash | 48.82M |
| Net Cash Per Share | 0.20 |
| Equity (Book Value) | 94.12M |
| Book Value Per Share | 0.39 |
| Working Capital | 54.86M |
Cash Flow
In the last 12 months, operating cash flow was 15.26 million and capital expenditures -463,000, giving a free cash flow of 14.80 million.
| Operating Cash Flow | 15.26M |
| Capital Expenditures | -463,000 |
| Depreciation & Amortization | 7.46M |
| Net Borrowing | n/a |
| Free Cash Flow | 14.80M |
| FCF Per Share | 0.06 |
Margins
Gross margin is 21.66%, with operating and profit margins of 14.94% and 14.51%.
| Gross Margin | 21.66% |
| Operating Margin | 14.94% |
| Pretax Margin | 14.67% |
| Profit Margin | 14.51% |
| EBITDA Margin | 17.86% |
| EBIT Margin | 14.94% |
| FCF Margin | 5.79% |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.84% |
| Shareholder Yield | -7.84% |
| Earnings Yield | 25.55% |
| FCF Yield | 10.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vaxart has an Altman Z-Score of -0.31 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.31 |
| Piotroski F-Score | 6 |